Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$6.8MCash on Hand
13.1mo Cash Runway
Follow CELZ by emailGet an email when CELZ reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CELZ, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Listing Received a Nasdaq notice on November 10, 2026 that the closing bid price was below $1.00 for 30 consecutive business days. The company has until May 10, 2027 to regain compliance and may be eligible for an additional 180-day grace period. Form 8-K · SEC filing
Nov 10, 2026 ·
Shareholder vote Annual meeting set for December 28, 2026 in Solana Beach, CA, with votes on five directors, advisory pay, Haynie & Company ratification, and an Equity Plan amendment adding an evergreen increase of up to 5% of outstanding shares each January through 2031. Form DEF 14A · SEC filing
Nov 6, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Sep 25, 2026 ·
Deal Company bought 4,000,000 BioDefense common shares from related party Creative Acquisition Corp. for $200,000 cash plus 1,000,000 company shares, raising its stake to 80%. CEO Timothy Warbington controls CAC. Form 8-K · SEC filing
Aug 31, 2026 ·
Shareholder vote Stockholders approved increasing authorized common shares from 25,000,000 to 100,000,000 and approved exercise in full of Investor Warrants for 5,580,680 shares issued in a June 30, 2026 private placement. Warrant proposal: 678,541 for, 344,460 against. Form 8-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jan 2027 · Phase 1/2 · Active Trial · Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain Registry primary completion date, not a results date
Jan 2027 · Phase 1/2 · Recruiting · Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes Registry primary completion date, not a results date
May 2029 · N/A · Upcoming Trial · Project PHOENIX: Molecular Signatures of Burn Pit Exposure Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not CELZ's own candidates): Propofol.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
CELZ holds $6.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $1.6M/quarter from operations,
an estimated runway of 13.1 months at that rate (BioRadar estimate, not company guidance).
Share count 7,597,557 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full CELZ picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CELZ and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.